BR112012023015A2 - imunoensaios para lenalidomida e talidomida - Google Patents

imunoensaios para lenalidomida e talidomida

Info

Publication number
BR112012023015A2
BR112012023015A2 BR112012023015A BR112012023015A BR112012023015A2 BR 112012023015 A2 BR112012023015 A2 BR 112012023015A2 BR 112012023015 A BR112012023015 A BR 112012023015A BR 112012023015 A BR112012023015 A BR 112012023015A BR 112012023015 A2 BR112012023015 A2 BR 112012023015A2
Authority
BR
Brazil
Prior art keywords
lenalidomide
thalidomide
immunoassays
immunogens
quantitation
Prior art date
Application number
BR112012023015A
Other languages
English (en)
Inventor
Volkov Alexander
Sard Howard
Blake Courtney Jodi
J Salamone Salvatore
Hedge Vishnumurthy
Original Assignee
Saladax Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saladax Biomedical Inc filed Critical Saladax Biomedical Inc
Publication of BR112012023015A2 publication Critical patent/BR112012023015A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Abstract

imunoensaios para lenalidomida e talidomida. a presente invenção refere-se a novos conjugados e imunógenos derivados de lenalidomida e anticorpos gerados por esses imunógenos são úteis em imunoensaios para a quantificação de monitoração de talidomida e lenalidomida e fluidos biológicos.
BR112012023015A 2010-03-12 2011-02-23 imunoensaios para lenalidomida e talidomida BR112012023015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/722,829 US8114621B2 (en) 2010-03-12 2010-03-12 Lenalidomide and thalidomide immunoassays
PCT/US2011/025883 WO2011112358A1 (en) 2010-03-12 2011-02-23 Lenalidomide and thalidomide immunoassays

Publications (1)

Publication Number Publication Date
BR112012023015A2 true BR112012023015A2 (pt) 2017-06-06

Family

ID=44560359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023015A BR112012023015A2 (pt) 2010-03-12 2011-02-23 imunoensaios para lenalidomida e talidomida

Country Status (9)

Country Link
US (5) US8114621B2 (pt)
EP (1) EP2544540B1 (pt)
JP (1) JP2013522594A (pt)
CN (2) CN102917587B (pt)
AU (1) AU2011224719B2 (pt)
BR (1) BR112012023015A2 (pt)
CA (1) CA2790508A1 (pt)
HK (1) HK1175071A1 (pt)
WO (1) WO2011112358A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029548B2 (en) * 2011-05-06 2015-05-12 Catabasis Pharmaceuticals, Inc. Fatty acid lenalidomide derivatives and their uses
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
WO2014031656A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
WO2014031662A2 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
WO2014121033A1 (en) 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) * 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US20220356185A1 (en) * 2018-07-06 2022-11-10 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
EP4009979A4 (en) * 2019-08-09 2023-08-23 The Regents of the University of California ANTIBODY-BASED CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES AND THEIR APPLICATIONS
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
IL294150A (en) 2019-12-23 2022-08-01 Kymera Therapeutics Inc Smarca joints and their uses
EP4121043A1 (en) 2020-03-19 2023-01-25 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
TW202304525A (zh) * 2021-04-14 2023-02-01 南韓商樂高化學生物科學股份有限公司 蛋白質降解劑偶聯物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996344A (en) 1972-05-15 1976-12-07 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies and use
US4016146A (en) 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20060024768A1 (en) * 2004-07-29 2006-02-02 Saladax Biomedical, Inc. Taxol immunoassay
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
EP2239573A3 (en) * 2005-03-30 2011-02-08 Saladax Biomedical Inc. Doxorubicin derivatives and conjugates for doxorubicin immunoassay
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
CN101501071A (zh) * 2006-05-31 2009-08-05 Lpath公司 对溶血磷脂酸具有反应性的免疫衍生部分
CN103145835B (zh) * 2008-07-17 2014-10-29 协和发酵麒麟株式会社 抗-***asc氨基酸转运蛋白2 (asct2)抗体

Also Published As

Publication number Publication date
US8114621B2 (en) 2012-02-14
EP2544540B1 (en) 2015-04-08
CN102917587A (zh) 2013-02-06
US20140024807A1 (en) 2014-01-23
US20120071632A1 (en) 2012-03-22
HK1175071A1 (en) 2013-06-28
US8440796B2 (en) 2013-05-14
US8293492B2 (en) 2012-10-23
US20110223611A1 (en) 2011-09-15
EP2544540A1 (en) 2013-01-16
CN104730254A (zh) 2015-06-24
WO2011112358A1 (en) 2011-09-15
AU2011224719B2 (en) 2014-10-23
CN102917587B (zh) 2015-04-29
US20120064549A1 (en) 2012-03-15
JP2013522594A (ja) 2013-06-13
EP2544540A4 (en) 2013-08-07
US20130211052A1 (en) 2013-08-15
AU2011224719A1 (en) 2012-09-06
CA2790508A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
FR23C1023I2 (fr) Anticorps anti-il-36r
CY2019040I2 (el) Aνti-il-23 αντισωματα
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
BRPI1011005A2 (pt) anticorpos anti-epcam
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
CR20110238A (es) Anticuerpos muc1*
BR112012030311A2 (pt) anticorpo
UY34206A (es) Anticuerpo monoclonal de interleucina-31
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK2825559T3 (da) Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
DK2651436T3 (da) Mycobakterie antigen sammensætning.
CR20130266A (es) PROTEÍNAS DE UNIÓN AL TNF-a
DK3275892T3 (da) Præfusions-rsv-f-antigener
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
CY1119173T1 (el) Νεα μορια αναστολεα jnk
CR20140127A (es) Anticuerpo anti-abtcr
BR112013015122A2 (pt) anticorpos anti-notch1
BRPI1014262A2 (pt) anticorpos específicos para caderina-17

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]